MDGL
Madrigal Pharmaceuticals, Inc.
MDGL lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
MDGL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
MDGL's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
MDGL PE Valuation
MDGL has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 87x next year's earnings.
MDGL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect MDGL to return to profit, with revenue growing. However, they disagree widely on these estimates.
MDGL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.89 | — |
| Q3 2026 | -$5.96 | +$6.84 |
| Q2 2026 | -$12.87 | -$0.23 |
| Q1 2026 | -$12.78 | +$5.06 |
| Q4 2025 | -$12.85 | +$9.05 |
| Q3 2025 | -$12.80 | +$12.28 |
| Q2 2025 | -$12.64 | +$12.86 |
| Q1 2025 | -$17.84 | +$5.25 |
| Q4 2024 | -$21.90 | -$1.96 |
MDGL is still losing money, but far less than before: $5.96 per share over the past year, against $25.50 at its worst in mid-2024.
MDGL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $431.3M | +50% |
| Q2 2026 | $364.3M | +71% |
| Q1 2026 | $311.3M | +127% |
| Q4 2025 | $321.1M | +211% |
| Q3 2025 | $287.3M | +362% |
| Q2 2025 | $212.8M | +1354% |
MDGL's revenue has grown year over year for 10 quarters in a row: $431M last quarter, up 50% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | +53 points |
| Q2 2026 | -15% | +6.7 points |
| Q1 2026 | -30% | +28 points |
| Q4 2025 | -19% | +46 points |
| Q3 2025 | -40% | +147 points |
| Q2 2025 | -22% | +1088 points |
| Q1 2025 | -58% | N/A |
| Q4 2024 | -65% | N/A |
MDGL's operating margin was 13% last quarter, up 53 points from the same quarter a year ago, near the top of its range since 2024.
MDGL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $116.6M | +48% |
| Q2 2026 | $19.1M | +$66.1M |
| Q1 2026 | -$171.3M | -$82.4M |
| Q4 2025 | -$133.1M | -$28.4M |
| Q3 2025 | $79M | +$146.8M |
| Q2 2025 | -$47.1M | +$88M |
| Q1 2025 | -$88.9M | +$60.6M |
| Q4 2024 | -$104.7M | -$23.7M |
MDGL has burned cash in almost every quarter: −$169M over the past year, against −$162M the year before.
MDGL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4% | +1.2M shares |
| 1 year | +35% | +7.8M shares |
| 3 years | +64% | +11.8M shares |
| 5 years | +82% | +13.7M shares |
| Available history | +96% | +14.9M shares |
MDGL has 30M diluted shares, up 35% from a year ago.
MDGL Net Leverage
MDGL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MDGL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 21.0 | Neutral |
MDGL's weekly RSI is 38 (neutral) and its Stochastic is 21 (neutral).
MDGL PE vs Healthcare Sector
MDGL has no meaningful PE right now: it lost money over the past year.
MDGL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $453.4 | 6.2% below |
| 20 week MA | $496.6 | 14% below |
| 50 week MA | $503.0 | 15% below |
| 100 week MA | $431.1 | 1.4% below |
| 200 week MA | $334.7 | 27% above |
MDGL has fallen below most of its moving averages, though it's still 27% above its 200-week average.
MDGL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.2 | $120.1 | +29% |
| 2021 | $120.1 | $87.3 | -27% |
| 2022 | $87.3 | $273.6 | +213% |
| 2023 | $273.6 | $231.4 | -15% |
| 2024 | $231.4 | $313.1 | +35% |
| 2025 | $313.1 | $598.9 | +91% |
| 2026 YTD | $598.9 | $425.2 | -29% |
MDGL has finished higher in four of the last six years, two of them by more than 50%. It's down 29% so far in 2026.